# Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

> **NCT03745326** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 5 (actual)

## Conditions studied

- Gastrointestinal Cancer
- Pancreatic Cancer
- Gastric Cancer
- Colon Cancer
- Rectal Cancer

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Aldesleukin
- **BIOLOGICAL:** anti-KRAS G12D mTCR PBL

## Key facts

- **NCT ID:** NCT03745326
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-16
- **Primary completion:** 2022-08-22
- **Final completion:** 2022-08-22
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03745326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03745326, "Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT03745326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*